Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
Company Blog Articles
On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer...
March 23, 2021
CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
View PDF with Supplemental Material Guo X, Mahlakõiv T, Ye Q, et al. CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK...
Thank you for joining the conference call to introduce the proposed merger agreement between GX Acquisition Corp. and Celularity Inc....
Your browser does not support the audio element. TranscriptThank you for joining the conference call to introduce the proposed merger...
As a company leading the innovation in off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases, Celularity has the...
LifebankUSA, powered by Celularity Inc, and the world’s most comprehensive company for cord, placenta and tissue banking, today unveils a...
